Drug innovation and the product pipeline in the cardiometabolic space is lagging due to the inherent time and cost of evidence generation needed for regulatory evaluation and approvals.
Live Webinar:
Date: June 9, 2022
Time: 11:00am ET / 8:00am PT Drug innovation and the product pipeline in the cardiometabolic space is lagging due to the inherent time and cost of evidence generation needed for regulatory evaluation and approvals. There are several factors that can impact delivery success, drive up costs and potentially delay time to market. They include: - Longer trial duration
- Intensive trial-related testing
- Poor medication adherence
- Delayed detection of key signals linked to endpoint capture
- Under-representation of the patient population for whom the treatment is intended
We will also highlight how (Medable) is working to address drug development challenges and improve the patient experience in the context of clinical studies. with its best-in-class digital products geared for the cardiometabolic sector. |
|
No comments